Category Archives: diagnostics

abcam discoveries

ABCAM

>

SEE WHAT ABCAM CAN DO FOR YOUR LAB?

Over the last 15 years, Abcam has remained committed to supporting scientists on their quest for discovery. We’ve focused on continually improving our high quality products and services by improving our global delivery times, enhancing our customer service offering, and increasing the validation information of our products. We’ve also expanded our product range beyond primary antibodies to include secondaries, proteins and peptides, lysates, biochemicals, immunoassays and other kits.

Advertisements

Leave a comment

August 15, 2013 · 5:09 pm

Zyoxel

zyoxel

Zyoxel develops and supplies cell culture platforms that support more physiologically relevant tissue models for pharmaceutical drug discovery applications:

  • Enabling the study of cellular behaviour and function in a more in vivo-like environment
  • Providing responses which closely replicate human clinical responses
  • Reducing the use of animals in testing
  • Reducing late stage clinical trial failures by identifying unsafe drugs and through selection of the most efficacious candidates earlier in development
  • Enabling more cost efficient drug development meaning that new medicines can be bought to market more quickly
Liver Chip enables cell culture in a 3D perfused state for advanced toxicity and efficacy testing

Liver Chip enables cell culture in a 3D perfused state for advanced toxicity and efficacy testing

Leave a comment

July 31, 2013 · 9:06 pm

Qvella

Canadian biotech company Qvella, headquartered in Toronto, is a molecular diagnostics company with new detection technology – preparing to bring a solution to the question of whether, and what, to prescribe when treating a possible infection is a problem.

If antibiotics are needed, they are most effective if used promptly – but the price of giving unnecessary treatment can be high, and includes not only the cost of the drugs themselves but also the growth of resistant strains of bacteria.

Currently, doctors can only get a definitive answer as to whether a patient is infected, and with what type of bacteria, after a sample from the patient is cultured in a lab, a process that takes between 24 and 72 hours. When a patient is in crisis, waiting that long simply isn’t an option. Sepsis, sometimes called a blood infection, is one such serious condition. It is the second cause of death among critical patients.

http://business.financialpost.com/2012/05/22/new-device-to-help-healthcare-workers-avoid-unnecessary-treatment/

https://www.htx.ca/Investment.aspx

Leave a comment

July 17, 2013 · 5:15 pm

TearLab Osmolarity System

TearLab (NASDAQ:TEAR; TSX:TLB) has reported third quarter net revenues of $1.2-million, an increase of 264% from $333,000 for the same period in 2011, and up 69% sequentially from $716,000 in the second quarter this year.

TearLab Osmolarity System

Growing doctor interest in our technology and the significant role that it can play in the objective diagnoses and management of dry eye disease drove our strong revenue performance in what is historically a seasonally weaker third quarter in the eye care industry. A total of 92 orders for TearLab systems were booked in the period.  Of those, 77 were through the company’s access programs, 6 were direct purchases and 9 were purchased outside of the U.S.

Leave a comment

May 29, 2013 · 5:20 pm

OXITEC

oxitec

Oxitec is a pioneer in controlling insects that spread disease and damage crops. They have developed an innovative new solution to controlling harmful insects pests.

http://www.oxitec.com

Leave a comment

March 10, 2013 · 4:02 pm